Bubendorf, Switzerland, Wednesday, April 26, 2017 – The Swiss Nanoscience Institute has granted CIS Pharma funding for an innovative project in the field of implantology. The Project is a collaboration between the University of Applied Science, FHNW in Muttenz and the High-tech Research Center in Basel. During this project a biocompatible membrane is developed to enhance tissue regeneration at the interface of soft and hard tissue. The membrane targets improved osseointegration of implants by preventing soft tissue cells from overgrowing the novel bone tissue. The membrane is designed to be compatible with common 3D printing technologies to enable patient specific applications.
About Swiss Nanoscience Institute
The Swiss Nanoscience Institute, SNI, is a center of excellence for nanosciences and nanotechnology. It was founded in 2006 by the University of Basel and the Canton Aargau in order to support research, education, and technology transfer in nanosciences and in nanotechnology. The SNI emerged from the National Center of Competence in Research, NCCR, Nanoscale Science, which was founded in 2001. In the SNI network, interdisciplinary teams of scientists of different research institutions in Northwestern Switzerland conduct basic and applied research and actively support knowledge and technology transfer to the industry. Within the study of nanoscience and the PhD School, the SNI trains young scientists and prepares them for careers in industry and academia. The SNI provides services to partners from research and industry, is involved in public relations and specifically supports various initiatives, particularly those aiming at interested young people and their teachers in natural sciences.
About CIS Pharma AG
CIS Pharma AG is an innovator in the life science industry. The company was founded in 1952 and is family owned. In our laboratories, we synthesize novel molecules, develop new biomaterials and create cutting-edge medical devices. Our mission is to improve the risk-benefit profile of therapeutics that are the standard of care, thereby improving patient’s experience and treatment outcome. Medical need, patient centricity and digital technology are key to our research and development programs. CIS Pharma is located in the region of Basel, Switzerland, one of the most successful life sciences locations in the world. For more information about the company, visit our website www.cis-pharma.com.